Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Martin Ingelsson

Showing results (101-110 of 217) with videos related to

Pageof 22
Sort By:
Neuropharmacology|February 12, 2022
In vivo imaging of alpha-synuclein with antibody-based PETSahar Roshanbin, Mengfei Xiong, Greta Hultqvist, et al.
Translational Neurodegeneration|June 25, 2020
Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriersJulia Remnestål, Linn Öijerstedt, Abbe Ullgren, et al.
Brain and Behavior|March 16, 2018
Early fine motor impairment and behavioral dysfunction in (Thy-1)-h[A30P] alpha-synuclein miceSara Ekmark-Lewén, Veronica Lindström, Astrid Gumucio, et al.
Free Radical Biology & Medicine|February 20, 2018
Corrigendum to "Low molar excess of 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote oligomerization of alpha-synuclein through different pathways" [Free Rad. Biol. Med. (2017) 421-431]Leire Almandoz-Gil, Hedvig Welander, Elisabeth Ihse, et al.
Experimental Neurology|September 6, 2003
APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosisHiroaki Fukumoto, Martin Ingelsson, Nina Gårevik, et al.
Free Radical Biology & Medicine|July 11, 2017
Low molar excess of 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote oligomerization of alpha-synuclein through different pathwaysLeire Almandoz-Gil, Hedvig Welander, Elisabet Ihse, et al.
Dementia and Geriatric Cognitive Disorders|May 8, 2009
Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotypeElin S Blom, Vilmantas Giedraitis, Henrik Zetterberg, et al.
Archives of Neurology|April 17, 2008
Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer diseaseHans Basun, Nenad Bogdanovic, Martin Ingelsson, et al.
Neuroscience Letters|May 7, 2014
The amyloid-β degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's diseaseJosef Pannee, Ulrika Törnqvist, Anni Westerlund, et al.
Acta Neuropathologica Communications|March 21, 2021
Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson's diseaseJuan F Reyes, Sara Ekmark-Léwen, Marina Perdiki, et al.
Pageof 22

Showing results (101-110 of 217) with videos related to

Sort By:
Pageof 22
Neuropharmacology|February 12, 2022
In vivo imaging of alpha-synuclein with antibody-based PETSahar Roshanbin, Mengfei Xiong, Greta Hultqvist, et al.
Translational Neurodegeneration|June 25, 2020
Altered levels of CSF proteins in patients with FTD, presymptomatic mutation carriers and non-carriersJulia Remnestål, Linn Öijerstedt, Abbe Ullgren, et al.
Brain and Behavior|March 16, 2018
Early fine motor impairment and behavioral dysfunction in (Thy-1)-h[A30P] alpha-synuclein miceSara Ekmark-Lewén, Veronica Lindström, Astrid Gumucio, et al.
Free Radical Biology & Medicine|February 20, 2018
Corrigendum to "Low molar excess of 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote oligomerization of alpha-synuclein through different pathways" [Free Rad. Biol. Med. (2017) 421-431]Leire Almandoz-Gil, Hedvig Welander, Elisabeth Ihse, et al.
Experimental Neurology|September 6, 2003
APOE epsilon 3/ epsilon 4 heterozygotes have an elevated proportion of apolipoprotein E4 in cerebrospinal fluid relative to plasma, independent of Alzheimer's disease diagnosisHiroaki Fukumoto, Martin Ingelsson, Nina Gårevik, et al.
Free Radical Biology & Medicine|July 11, 2017
Low molar excess of 4-oxo-2-nonenal and 4-hydroxy-2-nonenal promote oligomerization of alpha-synuclein through different pathwaysLeire Almandoz-Gil, Hedvig Welander, Elisabet Ihse, et al.
Dementia and Geriatric Cognitive Disorders|May 8, 2009
Rapid progression from mild cognitive impairment to Alzheimer's disease in subjects with elevated levels of tau in cerebrospinal fluid and the APOE epsilon4/epsilon4 genotypeElin S Blom, Vilmantas Giedraitis, Henrik Zetterberg, et al.
Archives of Neurology|April 17, 2008
Clinical and neuropathological features of the arctic APP gene mutation causing early-onset Alzheimer diseaseHans Basun, Nenad Bogdanovic, Martin Ingelsson, et al.
Neuroscience Letters|May 7, 2014
The amyloid-β degradation pattern in plasma--a possible tool for clinical trials in Alzheimer's diseaseJosef Pannee, Ulrika Törnqvist, Anni Westerlund, et al.
Acta Neuropathologica Communications|March 21, 2021
Accumulation of alpha-synuclein within the liver, potential role in the clearance of brain pathology associated with Parkinson's diseaseJuan F Reyes, Sara Ekmark-Léwen, Marina Perdiki, et al.
Pageof 22